Treatment Costs and Patient Outcomes With Use of Risperidone in a Public Mental Health Setting

Schiller, Mark; Shumway, Martha; Hargreaves, William A.

doi:10.1176/ps.50.2.228

Cited by 26 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33 Several economic evaluations have been published. These have used a range of study designs such as controlled and uncontrolled cohorts 117,126,[129][130][131][132][133][134][135][136][137][138][139][140][141][142] and controlled trials. 73,[143][144][145][146][147][148][149][150][151][152] A large number of modelling studies has been published, based on data from a variety of sources.…”

Section: The Economics Of Schizophreniamentioning

confidence: 99%

“…Nearly all the evaluations found that the new atypical antipsychotics were costeffective. 32,117,[130][131][132][133]135,137,139,141,[146][147][148]150,[152][153][154][155][157][158][159][160] The majority of comparisons of new atypical antipsychotics and conventional drugs considered risperidone or olanzapine. The systematic review and model by Bagnall and colleagues 32 considered a number of other new drugs in addition to these.…”

Section: The Economics Of Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Lewis

Davies²,

Jones³

et al. 2006

Health Technol Assess

135

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: SW Lewis received support for travel to meetings and honoraria for consultancies from AstraZeneca, Lilly, BristolMyersSquibb, Pfizer, Janssen, Wyeth, Lundbeck, GlaxoSmithKline and Novartis. L Davies received funding for preparing papers and attendance at meetings from Janssen, Hoechst Marion Roussel, Pfizer, AstraZeneca and Lundbeck, and project funding from Novartis. PB Jones received travel support to academic meetings from companies manufacturing drugs used in this study, and unrestricted use of honoraria and consultancy fees for some work for academic use in his department and elsewhere. TRE Barnes received travel support to academic meetings and honoraria for consultancy from companies manufacturing drugs used in this study, plus the award of a grant from Sanofi-Synthelabo for an investigator-initiated study. RM Murray received honoraria and advisory fees from pharmaceutical companies (paid into departmental research funds). R Kerwin received honoraria and advisory fees from pharmaceutical companies and received research grants for non-clinical research from Novartis. D Taylor received honoraria for a lecture and consultancy from manufacturers of atypical antipsy...

show abstract

Section: The Economics Of Schizophreniamentioning

confidence: 99%

Section: The Economics Of Schizophreniamentioning

confidence: 99%

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Lewis

Davies²,

Jones³

et al. 2006

Health Technol Assess

135

View full text Add to dashboard Cite

show abstract

“…Retrospective comparisons of patients receiving several types of antipsychotic drugs represent a better alternative to using patientrecord data. In this review, the authors identified 13 studies of this type [98][99][100][101][102][103][104][105][106][107][108][109][110][111] listed in TABLE 3. While the evidence of retrospective comparisons is not restricted by the regression to the mean problem, they are still constrained by the limited information provided by the record systems they use as data bases because most record systems do not include standardized outcome measures.…”

Section: Effects Of Antipsychotic Medication On the Costs Of Schizophmentioning

confidence: 99%

“…From the 13 retrospective comparison studies identified for this review, three compared clozapine against conventional antipsychotics [98,103,107], four compared risperidone with conventional agents [100][101][102]106] and five tested olanzapine against risperidone [104,105,[108][109][110].…”

Section: Retrospective Comparisonsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of antipsychotic medication on the cost of schizophrenia

Kilian

Becker

2005

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

A systematic literature search regarding the factors influencing the costs of schizophrenia and of comparative studies on the impact of antipsychotic treatment on the costs of schizophrenia between 1990 and 2004 was conducted. Altogether, 11 studies on factors influencing the costs of schizophrenia and 39 pharmacoeconomic studies on the comparative effects of antipsychotic medications on costs of schizophrenia were identified. Considering the factors influencing the costs of schizophrenia, the results of the review revealed only little systematic knowledge due to a great variation of methodologic standards and variables included. With regard to the effects of antipsychotic treatment, most studies compared atypical with conventional antipsychotic compounds. Results of these studies are inconsistent, and due to differences in methodologic standards, it is not possible to draw an evidence-based conclusion on the economic effects of a particular type of antipsychotic treatment. Consensus on the main outcome indicators of antipsychotic treatment and common standards of outcome measurement as well as economic analysis methods are necessary to overcome the current lack of empirical evidence.

show abstract